Navepegritide
Overview
Navepegritide (brand: Yuviwel) is a PEGylated C-type natriuretic peptide (CNP) analog that activates NPR-B receptor signaling to promote endochondral bone growth at growth plates. FDA approved February 27, 2026 to increase linear growth in pediatric patients 2 years and older with achondroplasia and open epiphyses. Administered by subcutaneous injection. Developed by BioMarin Pharmaceutical.
Protocols & dosing
Detailed dosing protocols have not yet been catalogued.
FDA & legal status
Navepegritide is approved by the U.S. Food and Drug Administration for one or more clinical indications. Refer to the prescribing information for full safety and dosing details.
| Country | Status |
|---|---|
| United States | FDA approved |
| United Kingdom | Prescription-only / not licensed |
| Canada | Prescription-only / Schedule F if licensed |
| Australia | TGA-scheduled |
Vendor information
PeptideSciences101 does not endorse vendors. For transparency metrics and third-party testing notes, see the vendor directory.
References
No external sources have been catalogued for this article yet.
Related peptides
- Abaloparatide — Advanced bone anabolic
- BPC-157 — Bone and cartilage healing
- Calcitonin — FDA-approved bone resorption inhibitor
- Collagen Peptides — Structural bone and joint support
- GHK-Cu — Bone remodeling support
- Pentosan Polysulfate — Cartilage and joint protection